Search Results - Jon Chung

Refine Results
  1. 1
    Cdk2 Is Required for p53-Independent G2/M Checkpoint Control

    Cdk2 Is Required for p53-Independent G2/M Checkpoint Control by Jon Chung, Fred Bunz

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor

    Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor by Andrew R. Larsen, Ren-Yuan Bai, Jon Chung, Alexandra Borodovsky, Charles M. Rudin, Gregory J. Riggins, Fred Bunz

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype

    Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype by Ethan Sokol, Dean C. Pavlick, Garrett M. Frampton, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Tamara L. Lotan, Drew M. Pardoll, Jon Chung, Emmanuel S. Antonarakis

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma

    Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma by Andrea Necchi, Russell W. Madison, Sumanta K. Pal, Jeffrey S. Ross, Neeraj Agarwal, Guru Sonpavde, Monika Joshi, Ming Yin, Vincent A. Miller, Petros Grivas, Jon Chung, Siraj M. Ali

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma

    Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma by Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil K. Dasyam, Nathan Bahary

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy

    Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy by Hyunseok Kang, Dean Pettinga, Adrian D. Schubert, Paul W. Ladenson, Douglas W. Ball, Jon Chung, Alexa B. Schrock, Russell W. Madison, Garrett M. Frampton, Phil Stephens, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

    Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity by Ethan S. Sokol, Dean C. Pavlick, Hossein Khiabanian, Garrett M. Frampton, Jeffrey S. Ross, Jeffrey P. Gregg, Primo N. Lara, Steffi Oesterreich, Neeraj Agarwal, Andrea Necchi, Vincent A. Miller, Brian M. Alexander, Siraj M. Ali, Shridar Ganesan, Jon Chung

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer

    Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer by Alexa B. Schrock, Allison W. Welsh, Jon Chung, Dean C. Pavlick, Eric Bernicker, Ben Creelan, Brady Forcier, Jeffrey S. Ross, Philip J. Stephens, Siraj M. Ali, Ibiayi Dagogo‐Jack, Alice T. Shaw, Tianhong Li, Sai‐Hong Ignatius Ou, Vincent A. Miller

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer

    Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer by Ethan Sokol, Yongzhi Feng, Dexter X. Jin, Ahmed Basudan, A.V. Lee, Jennifer M. Atkinson, Jun‐Jiang Chen, Philip J. Stephens, Garrett M. Frampton, Piyush B. Gupta, Jeffrey S. Ross, Jon Chung, Steffi Oesterreich, Siraj M. Ali, Ryan J. Hartmaier

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib

    HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib by S.-H.I. Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Charbel Haddad, Gary Steinecker, Melissa L. Johnson, Barbara J. Gitlitz, Jon Chung, Paulo Vidal Campregher, J.S. Ross, P. Stephens, V.A. Miller, James Suh, Siraj M. Ali, Vamsidhar Velcheti

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers

    Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers by Aatur D. Singhi, Ben George, Joel Greenbowe, Jon Chung, James Suh, Anirban Maitra, Samuel J. Klempner, Andrew Hendifar, Javle Milind, Talia Golan, Randall E. Brand, Amer H. Zureikat, Somak Roy, Alexa B. Schrock, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Nathan Bahary

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

    HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib by Sai‐Hong Ignatius Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa L. Johnson, Barbara J. Gitlitz, Jon Chung, Paulo Vidal Campregher, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, James Suh, Siraj M. Ali, Vamsidhar Velcheti

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

    Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors by Jon Chung, Ninad Dewal, Ethan Sokol, Paul Mathew, Robert P. Whitehead, Sherri Z. Millis, Garrett M. Frampton, Gennady Bratslavsky, Sumanta K. Pal, Richard J. Lee, Andrea Necchi, Jeffrey P. Gregg, Primo N. Lara, Emmanuel S. Antonarakis, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Neeraj Agarwal

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors

    Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors by Andrea Necchi, Gennady Bratslavsky, Oleg Shapiro, Julia A. Elvin, Jo‐Anne Vergilio, Jonathan Keith Killian, Nhu Ngo, Shakti Ramkissoon, Eric A. Severson, Amanda Hemmerich, Siraj M. Ali, Jon Chung, Prasanth Reddy, Vincent A. Miller, Alexa B. Schrock, Laurie M. Gay, Jeffrey S. Ross, Joseph M Jacob

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

    Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer by Smruthy Sivakumar, Dexter X. Jin, Hanna Tukachinsky, Karthikeyan Murugesan, Kimberly McGregor, Natalie Danziger, Dean C. Pavlick, Ole Gjoerup, Jeffrey S. Ross, Robert J. Harmon, Jon Chung, Brennan Decker, Lucas Dennis, Garrett M. Frampton, Luciana Molinero, Steffi Oesterreich, Jeffrey M. Venstrom, Geoffrey R. Oxnard, Priti S. Hegde, Ethan Sokol

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

    Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus by Alexa B. Schrock, Dean C. Pavlick, Samuel J. Klempner, Jon Chung, Brady Forcier, Allison W. Welsh, Lauren Young, B Leyland-Jones, Rodolfo Bordoni, Richard D. Carvajal, Joseph Chao, Razelle Kurzrock, Jason K. Sicklick, Jeffrey S. Ross, Philip J. Stephens, Craig Devoe, Fadi Braiteh, Siraj M. Ali, Vincent A. Miller

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

    Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study by Andrea Necchi, Andrea Anichini, Daniele Raggi, Alberto Briganti, Simona Massa, Roberta Lucianò, Maurizio Colecchia, Patrizia Giannatempo, Roberta Mortarini, Marco Bianchi, Elena Farè, Francesco Monopoli, Renzo Colombo, Andrea Gallina, Andrea Salonia, A. Messina, Siraj M. Ali, Russell W. Madison, Jeffrey S. Ross, Jon Chung, Roberto Salvioni, Luigi Mariani, Francesco Montorsi

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer

    Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer by Marco Bandini, Jeffrey S. Ross, Daniele Raggi, Andrea Gallina, Maurizio Colecchia, Roberta Lucianò, Patrizia Giannatempo, Elena Farè, Filippo Pederzoli, Marco Bianchi, Renzo Colombo, Giorgio Gandaglia, Nicola Fossati, Laura Marandino, Umberto Capitanio, Federico Dehò, Siraj M. Ali, Russell W. Madison, Jon Chung, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Andrea Necchi

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

    Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer by Pingping Mao, Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco, Pedro Exman, Seth A. Wander, Adrienne G. Waks, Utthara Nayar, Jon Chung, Samuel S. Freeman, Orit Rozenblatt–Rosen, Vincent A. Miller, Federica Piccioni, David E. Root, Aviv Regev, Eric P. Winer, Nancy U. Lin, Nikhil Wagle

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    RET rearrangements are actionable alterations in breast cancer

    RET rearrangements are actionable alterations in breast cancer by Bhavna Paratala, Jon Chung, Casey Williams, Bahar Yilmazel, Whitney Petrosky, Kirstin Williams, Alexa B. Schrock, Laurie M. Gay, Ellen Lee, Sonia Dolfi, Kien Pham, Stephanie K. Lin, Ming Yao, Atul Kulkarni, Frances DiClemente, Chen Liu, Lorna Rodríguez-Rodríguez, Shridar Ganesan, Jeffrey S. Ross, Siraj M. Ali, Brian Leyland‐Jones, Kim M. Hirshfield

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: